Conferences
SUO 2017: Promise of Checkpoint Inhibitors for BCG-Unresponsive NMIBC
November 30, 2017
SUO 2017: Aberrant Histology in NMIBC - What Do We Know and Not Know?
November 30, 2017
SUO 2017: High Competing Risks Minimize Real-world Utility Of Adjuvant Targeted Therapy In Renal Cell Carcinoma: A Population-based Analysis
November 30, 2017
SUO 2017: Pathologic Downstaging Following Neoadjuvant Chemotherapy In Patients With High-risk Upper Tract Urothelial Carcinoma
November 30, 2017
SUO 2017: Post-TUR Mitomycin C Debate: Should it be Standard of Care?
November 30, 2017
SUO 2017: Is Gemcitabine the Answer?
November 30, 2017
SUO 2017: Preoperative Multiplex Nomogram For Prediction Of high-risk non-organ confined Upper-Tract Urothelial Carcinoma
November 30, 2017
SUO 2017: Thermo Reversible Hydrogel Based Delivery MitoGel™ - Upper Tract Urothelial Carcinoma
November 30, 2017
SUO 2017: Post-Transurethral Resection Intravesical Mitomycin C Debate
November 30, 2017
SUO 2017: InPACT Trial - Answering the Unanswered Questions
November 30, 2017
SUO 2017: Optimal Timing of Adjuvant and Salvage Radiation Following Radical Prostatectomy
November 30, 2017
SUO 2017: Using Genomic Biomarkers to Select Patients for Postoperative Therapies for Prostate Cancer
November 30, 2017
SUO 2017: Genomics and Molecular Testing after Radical Prostatectomy
November 30, 2017
SUO 2017: Trials, Trends, and Models: Synthesizing the Evidence on Prostate Cancer Screening
November 30, 2017
SUO 2017: When First Line Chemotherapy Fails - Locally Advanced or Metastatic Penile Cancer Patient
November 30, 2017
SUO 2017: Immunotherapy of Genitourinary Cancer: Renal Cell Carcinoma – Emerging Data for Locally Advanced and Metastatic Disease
November 30, 2017
SUO 2017: From Biopsy, AS vs Rx: Stratifying Risk in Localized PCa
November 30, 2017
SUO 2017: Currently Approved Immunotherapy for Bladder Cancer
November 30, 2017